Plus, news about BioNTech, Roche, Boehringer Ingelheim, CervoMed, Genmab, Inozyme Pharma, Valo Therapeutics and Agomab:
Mineralys Therapeutics’ $250M follow-on offering: Stellar Phase 3 data for the company’s blood pressure drug lorundrostat sent ...
↧
